ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) Revenue
ResMed Inc.'s revenue for fiscal 2026 was $5.7B, up 9.85% from $5.1B in fiscal 2025. Over the past ten years it has ranged from $1.7B (fiscal 2015) to $5.7B (fiscal 2026) — the current reading is the highest in ten years. Revenue has risen for 11 consecutive fiscal years. ResMed Inc. ranks 8th of 51 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Annual
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $5.7B | 9.85% |
| FY2025 | $5.1B | 9.84% |
| FY2024 | $4.7B | 10.95% |
| FY2023 | $4.2B | 18.02% |
| FY2022 | $3.6B | 11.93% |
| FY2021 | $3.2B | 8.11% |
| FY2020 | $3.0B | 13.44% |
| FY2019 | $2.6B | 11.38% |
| FY2018 | $2.3B | 13.23% |
| FY2017 | $2.1B | 12.40% |
Quarterly
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.5B | 2.25% |
| Mar 2026 | $1.4B | 0.60% |
| Dec 2025 | $1.4B | 6.53% |
| Sep 2025 | $1.3B | (0.92%) |
| 42 more quarters | Free account |
Against its own ten years
Low $1.7B
High $5.7B
Ten-year median
$3.1B
Current reading's percentile
100
Revenue against peers
| Company | Revenue |
|---|---|
| MDLN Medline Inc. compare | $29.7B |
| BDX Becton, Dickinson and Company compare | $22.4B |
| BAX Baxter International Inc. compare | $11.5B |
| ALC Alcon compare | $10.9B |
| SOLV Solventum Corporation compare | $8.3B |
| RMD ResMed Inc. | $5.7B |
| COO The Cooper Companies, Inc. compare | $4.2B |
| WST West Pharmaceutical Services, Inc. compare | $3.3B |
| RGEN Repligen Corporation compare | $785.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RMD
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement